Sadeghi, MinooshGholizadeh, MajidSafataj, NedaTahmasebivand, MahsaMohajeri, GholamrezaLotfi, HajieBostanabad, Saber YariSafar, BehnazSalehi, Mansoor2024-01-312024-01-312023Sadeghi, M., Gholizadeh, M., Safataj, N., Tahmasebivand, M., Mohajeri, G., Lotfi, H., Bostanabad, S. Y., Safar, B., & Salehi, M. (2023). GLIS2 and CCND1 expression levels in breast cancer patients. Breast Disease, 42(1), pp. 251–259. https://doi.org/10.3233/BD-2200680888-60081558-1551https://doi.org/10.3233/BD-220068https://hdl.handle.net/20.500.13055/646Breast cancer (BC) is the most prevalent cancer in women, with increasing incidence and death rates in recent years. Disruptions of different signaling pathways partially cause breast cancer. Hence, different genes through particular pathways are involved in BC tumorigenesis. METHODS: In this study, we evaluated the expression level of GLIS2 and CCND1 genes in 50 patients. Also, in-silico analyses were used to enrich related signaling pathways involving the mentioned genes. RESULTS: The results showed an increased expression level of Cyclin D1 and decreased expression level of GLIS2 in BC patients. Moreover, a relationship between aberrant expression levels of GLIS2 and CCND1 and BC development was determined. CONCLUSION: These observations could help uncover new therapeutic targets for treating patients with BC in the progressive stage.eninfo:eu-repo/semantics/closedAccessBreast CancerCCND1GLIS2Signaling PathwayArticle10.3233/BD-2200684212512592-s2.0-85168059642PMID: 37574724Q4